Tanvex BioPharma, Inc. (TPE: 6541)

Market Cap	11.58B
Revenue (ttm)	34.56M
Net Income (ttm)	-1.81B
Shares Out	164.03M
EPS (ttm)	-12.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,882
Open	72.20
Previous Close	71.40
Day's Range	70.90 - 72.70
52-Week Range	35.05 - 80.00
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Tanvex BioPharma

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 149
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6541

Financial Performance

In 2023, Tanvex BioPharma's revenue was 61.41 million, an increase of 174.11% compared to the previous year's 22.40 million. Losses were -2.14 billion, 30.2% more than in 2022.